Blood Adv
Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure.
Related Questions
Can results from emerging AML data be extrapolated to high risk MDS populations?
Is there data to guide the choice of continuing the HMA in combinati...
New comment by at Memorial Hospital for Cancer & Allied Diseases ( December 4, 2020)
Agree with Dr. @Eytan M. Stein. Due to uncertain benefit and likely additive myelotoxicity of venetoclax, suggest clinical trial after HMA refractoriness demonstrated.